SCHEMBL29239235

SCHEMBL29239235

CC(C)(C)OC(=O)NCC1CCN(c2ccc(CN)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 1/20 0.52
SKP1 P63208 1/20 0.52
SKP2 Q13309 1/20 0.52
ACACB O00763 7/20 0.51
ACACA Q13085 6/20 0.51
DRD2 P14416 2/20 0.50
NAMPT P43490 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
F10 P00742 2/20 0.46
KDM4E B2RXH2 1/20 0.45
PKM P14618 1/20 0.45
TPSAB1 Q15661 1/20 0.44
GPR119 Q8TDV5 2/20 0.43
TGFBR1 P36897 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29311592 0.89 CKS1B (0.53) CKS1BSKP1SKP2ACACBACACA
SCHEMBL4695534 0.89 ACACB (0.53) CKS1BSKP1SKP2ACACBACACA
SCHEMBL5653703 0.88 CKS1B (0.53) CKS1BSKP1SKP2ACACBACACA
SCHEMBL12916519 0.87 GPR119 (0.57) CKS1BSKP1SKP2ACACBACACA
SCHEMBL16394312 0.86 CKS1B (0.53) CKS1BSKP1SKP2ACACBACACA
SCHEMBL8222029 0.86 CKS1B (0.53) CKS1BSKP1SKP2ACACBACACA
SCHEMBL4116060 0.85 CKS1B (0.64) CKS1BSKP1SKP2ACACBACACA
SCHEMBL948774 0.84 CKS1B (0.52) CKS1BSKP1SKP2ACACBACACA
SCHEMBL803332 0.83 CKS1B (0.56) CKS1BSKP1SKP2ACACBACACA
SCHEMBL9984934 0.83 CKS1B (0.56) CKS1BSKP1SKP2ACACBACACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250381196-A1 ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) 2025-12-18 US disclosed
US-20250241908-A1 ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES NINGBO MEISHAN BONDED PORT AREA ZHEJIANG UNITED INVESTMENT MANAGEMENT CO., LTD. (CN) 2025-07-31 US disclosed
CN-119997953-A Alpha protein kinase 1 inhibitors for the treatment of kidney diseases and kidney related diseases 上海药苑生物科技有限公司 2025-05-13 CN disclosed
US-20240226094-A1 ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE XU, Cong (CN) 2024-07-11 US disclosed
CN-118103045-A Alpha protein kinase 1 inhibitors for the treatment of kawasaki disease 上海药苑生物科技有限公司 2024-05-28 CN disclosed
US-20240109853-A1 ALPHA PROTEIN KINASE 1 INHIBITORS AND METHODS OF USE TIANJIN HONGKE BAISHI QIXIN VENTURE CAPITAL PARTNERSHIP (LIMITED PARTNERSHIP) (CN) 2024-04-04 US disclosed
CN-116670133-A Alpha protein kinase 1 inhibitors and methods of use 上海药苑生物科技有限公司 2023-08-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226094-A1 ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE PHKA1, PHKA2, PHKG1 CKS1B 284/4885SKP1 178/4885SKP2 1034/4885
US-20240109853-A1 ALPHA PROTEIN KINASE 1 INHIBITORS AND METHODS OF USE PHKA1, PHKA2, PHKG1 CKS1B 145/4885SKP1 277/4885SKP2 590/4885
US-20250241908-A1 ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES PHKA1, PHKA2, PHKG1 CKS1B 221/4885SKP1 230/4885SKP2 382/4885
US-20250381196-A1 ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES PHKA1, PHKA2, PHKG1 CKS1B 166/4885SKP1 294/4885SKP2 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.